Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
Takuji Okusaka, Masafumi Nakamura, Masahiro Yoshida, Masayuki Kitano, Yoshinori Ito, Nobumasa Mizuno, Keiji Hanada, Masato Ozaka, Chigusa Morizane, Yoshifumi Takeyama, Yasunari Sakamoto, Dai Inoue, Ken Kamata, Manabu Kawai, Atsushi Kanno, Masahiro Serikawa, Atsushi Sofuni, Yukiko Takayama, Hiroyuki Matsubayashi, Takao Ohtsuka, Shunsuke Onoe, Manabu Kawai, Masayuki Sho, Tsutomu Fujii, Ippei Matsumoto, Ryusei Matsuyama, Masamichi Mizuma, Tomohisa Yamamoto, Tatsuya Ioka, Hidetoshi Eguchi, Masanori Someya, Kohei Nakata, Satoaki Nakamura, Takayuki Ohguri, Makoto Shinoto, Masanori Someya, Satoaki Nakamura, Tatsuya Ioka, Makoto Ueno, Takao Itoi, Hiroyuki Isayama, Hironari Kato, Yousuke Nakai, Keiichi Uemura, Takuya Oyakawa, Hatoe Sakamoto, Yoichi Shimizu, Keita Tagami, Tetsuya Tsuji, Maiko Fujimori, Shuichi Mitsunaga, Masanori Mori, Takashi Yokokawa, Masashi Kanai, Hiroyuki Matsubayashi, Shoji Osada, Yoichi Shimizu, Sawako Furutani, Yoshiyuki Majima, Masanori Mori, Naohiko YAMAGUCHI, Natsuki Narita, Akiko Okumura, Kyoko Shima, Yasunari Sakamoto, Keiko Kondo, Nobuya Akizuki, Reiko Ashida, Naoki Ikenaga, Yasutaka Ishii, Shigeto Ishii, Noboru Ideno, Koji Inaba, Yu Uneno, Rei Umezawa, Katsuhisa Ohgi, Akihiro Ohba, Shunsuke Omoto, Yoshiro Okajima, Yuka Ono, Akiyoshi Kasuga, Keiko Kamei, Hiroshi Kurahara, Hidekazu Kuramochi, Keisuke Kurihara, Takamichi Kuwahara, Kazuo Kobayashi, Satoshi Kobayashi, Tomohiro Kondo, Kei Saito, T. Shiga, Taro Shibuki, Kazuto Shibuya, Akinori Shimizu, Yasuhiro Shimizu, Hidenori Takahashi, Naminatsu Takahara, Takaaki Tsuchiya, Takayoshi Tsuchiya, Tomofumi Tsuboi
Abstract
OBJECTIVES: Clinical Practice Guidelines for Pancreatic Cancer was first published in 2006 by the Japan Pancreas Society, and revised in 2009, 2013, 2016, and 2019. In July 2022, Clinical Practice Guidelines for Pancreatic Cancer was newly revised in Japanese. METHODS: For this revision, we developed an entirely new guideline according to the Minds Manual for Guideline Development 2020, which includes the concepts of GRADE-Grading Recommendations Assessment, Development, and Evaluation, to enable a better understanding of the current guidelines. Patients and the public were actively involved in both the development and implementation of the guideline. RESULTS: The guideline includes algorithms for diagnosis, treatment, chemotherapy, and precision medicine of pancreatic cancer, and addresses 7 subjects: diagnosis, surgical therapy, adjuvant therapy, radiation therapy, chemotherapy, stent therapy, and supportive & palliative medical care. It includes 73 clinical questions and 112 statements. The statements correspond to the clinical questions, evidence levels, recommendation strengths, and agreement rates. CONCLUSIONS: This guideline represents the most standard clinical and practical management guideline available until date in Japan. This is the English synopsis of the Clinical Practice Guidelines for Pancreatic Cancer 2022 in Japanese, and is an attempt to disseminate the Japanese guideline worldwide to introduce the Japanese approach to the clinical management of pancreatic cancer.